Champions Oncology (CSBR) Other Non-Current Assets (2011 - 2026)
Champions Oncology (CSBR) recorded quarterly Other Non-Current Assets of $196000.0 in Q1 2026, little changed quarter-over-quarter from $196000.0 in Q4 2025, and up 5.95% on a YoY basis from $185000.0 in Q1 2025.
Champions Oncology (CSBR) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Champions Oncology's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $196000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 5.95% year-over-year to $196000.0; the TTM figure through Jan 2026 stood at $196000.0 (up 5.95% YoY), while the FY2025 annual figure was $196000.0, up 5.95% from the prior year.
- Other Non-Current Assets was $196000.0 for Q1 2026 at Champions Oncology, roughly flat from $196000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $196000.0 in Q2 2025 to a low of $15000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $127529.4 across 5 years, with a median of $185000.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 82.56% in 2022, then jumped 1133.33% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $15000.0 in 2022, then surged by 1133.33% to $185000.0 in 2023, then changed by 0.0% to $185000.0 in 2024, then rose by 5.95% to $196000.0 in 2025, then changed by 0.0% to $196000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $196000.0 (Q1 2026), $196000.0 (Q4 2025), and $196000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 196,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 196,000.00 |
| Oct 31, 2025 | 196,000.00 |
| Jul 31, 2025 | 196,000.00 |
| Apr 30, 2025 | 196,000.00 |
| Jan 31, 2025 | 185,000.00 |
| Oct 31, 2024 | 185,000.00 |
| Jul 31, 2024 | 185,000.00 |
| Apr 30, 2024 | 185,000.00 |
| Jan 31, 2024 | 185,000.00 |
| Oct 31, 2023 | 185,000.00 |
| Jul 31, 2023 | 184,000.00 |
| Apr 30, 2023 | 15,000.00 |
| Jan 31, 2023 | 15,000.00 |
| Oct 31, 2022 | 15,000.00 |
| Jul 31, 2022 | 15,000.00 |
| Apr 30, 2022 | 15,000.00 |
| Jan 31, 2022 | 15,000.00 |
| Oct 31, 2021 | 15,000.00 |
| Jul 31, 2021 | 86,000.00 |
| Apr 30, 2021 | 15,000.00 |